



8:00 PM – 9:30 PM Mumbai, India (IST)
10:30 PM – 12:00 AM Beijing, China (CST)
3:30 PM – 5:00 PM London, UK (BST)

[CLICK HERE TO JOIN WEBINAR](#)

STP-I Continuing Education Webinar: Preclinical safety findings with systemically administered oligonucleotides and strategies to adjudicate them

Welcome to STP-I webinar on "Preclinical Safety Findings with Systemically Administered Oligonucleotides and Strategies to Adjudicate Them." Over the past decade, therapeutic oligonucleotide drugs (ONDs) have made significant strides in chemistry and mechanistic understanding, leading to successful clinical applications. This session, led by Dr. Kuldeep Singh from Wave Life Sciences, will highlight the common toxicities, improved mechanistic insights, and safety assessment activities for ONDs. We will explore challenges such as off-target effects, immune stimulation, and organ-specific toxicities, and discuss innovative strategies to mitigate these risks. Join STP-India as we delve into the complexities of preclinical safety to advance safer, more effective oligonucleotide therapies.



Dr. Kuldeep Singh

Dr. Kuldeep Singh, BVSc, PS, PhD, Diplomate ACVP
Head of Pathology, Wave Life Sciences, Massachusetts, USA

Kuldeep Singh is currently the Head of Pathology at Wave Life Sciences. He obtained his BVSc (Bachelor of Veterinary Sciences) from G.B. Pant University of Agriculture and Technology, MS from Utrecht University, The Netherlands, and PhD and residency in anatomic pathology from Oklahoma State University. He joined the American College of Veterinary Pathologists as a diplomate in 2009.

Prior to joining Wave Life Sciences, he worked as an Investigative Pathologist at Sanofi and as a Director of Toxicologic Pathology at WuXiApptech. He served the University of Illinois as Head of Anatomic Pathology and Clinical Associate Professor in the College of Veterinary Medicine, Urbana-Champaign.

His professional interests include oligonucleotides, toxicology, biomarker identification, safety assessment, animal model characterization, and investigative and digital pathology. Kuldeep has authored or coauthored more than 55 peer reviewed articles, book chapters, and more than 75 abstracts and posters. He is currently an adhoc reviewer for 14 journals. Kuldeep has presented in multiple national and international conferences as an invited speaker.

He is a primary or co-investigator on 2 patents (application filed) based on oligonucleotides.

For joining webinar Microsoft Teams click following link

[CLICK HERE TO JOIN WEBINAR](#)

For technical questions, please contact STP-I at drprafulvetpath@gmail.com OR stpi.india@gmail.com